GLP-1 Telehealth Safety Report: The Standards Every Platform Should Meet in 2026

The GLP-1 telehealth market has grown faster than any telehealth segment in history. Hundreds of platforms now offer semaglutide and tirzepatide prescriptions through virtual consultations. Some are excellent. Some are mediocre. And some operate with standards that would alarm any informed patient. This report establishes what good looks like — the minimum safety standards every GLP-1 telehealth platform should meet in 2026.

Standard 1: Licensed Prescribers in Every Patient's State

This sounds obvious, but it's violated more often than patients realize. A legitimate GLP-1 telehealth platform employs or contracts with physicians, nurse practitioners, or physician assistants who hold active, unrestricted medical licenses in the state where the patient physically resides at the time of consultation.

"Active and unrestricted" means the provider's license has not been suspended, revoked, placed on probation, or limited by the state medical board. Every patient has the right to verify this — and we'll show you exactly how in our companion article on license verification.

The rise of interstate medical license compacts (IMLC) has made multi-state practice easier for physicians, but the fundamental requirement remains: the prescriber must be authorized to practice in the patient's state. Platforms that route patients to out-of-state providers without proper licensing are operating outside the law, even if their marketing suggests otherwise.

Standard 2: Genuine Medical Evaluation Before Prescribing

A GLP-1 prescription requires a clinical evaluation — not a questionnaire rubber stamp. The minimum standard for a legitimate pre-prescribing evaluation includes:

• Medical history review — current medications, prior weight loss attempts, relevant conditions (thyroid disease, pancreatitis, gallbladder disease, eating disorders, pregnancy status)
• Contraindication screening — personal or family history of MTC, MEN2, active pancreatitis, pregnancy
• BMI/eligibility verification — documented BMI ≥30 or ≥27 with comorbidities
• Baseline lab work — at minimum CMP, A1C, and TSH. Some platforms order these before the first consultation; others prescribe and require labs within 30 days. Both approaches are acceptable, but prescribing without ever requiring labs is not.
• Mental health screening — at least basic questions about mood, eating behaviors, and suicidal ideation

If a platform prescribes GLP-1 medication based solely on a brief online form without any synchronous interaction (video or phone) with a licensed prescriber, that platform is not meeting the standard of care. Period.

Standard 3: Verified Pharmacy Partnerships

Where your medication comes from matters as much as who prescribes it. Legitimate telehealth platforms source medications from pharmacies that meet verifiable standards:

For brand-name medications: Licensed retail or mail-order pharmacies with state board verification and DEA registration.

For compounded medications: 503A or 503B compounding pharmacies with current state licensing, PCAB accreditation (Pharmacy Compounding Accreditation Board) preferred, and documented compliance with USP 795/797/800 standards for sterile and non-sterile compounding.

A platform should be able to tell you the name and location of the pharmacy filling your prescription. If they can't or won't, that opacity is itself a risk indicator.

Standard 4: Follow-Up Care and Ongoing Monitoring

GLP-1 prescribing is not a one-time transaction — it's an ongoing clinical relationship. The minimum follow-up standard includes:

• Scheduled check-in at each dose increase during titration (typically every 4 weeks)
• Provider accessibility for questions and side effect management between scheduled visits
• Lab work monitoring at baseline, 3 months, 6 months, and annually
• Clear protocol for adverse events — the patient should know who to contact and how quickly they'll get a response

Standard 5: Transparent Pricing and Refund Policies

Legitimate platforms publish their pricing clearly before the patient commits. This includes the consultation fee, medication cost, shipping fees, and any ongoing subscription charges. Hidden fees discovered after enrollment are a trust violation even if they're technically disclosed in fine print.

Refund policies should be clearly stated. If a patient is denied treatment after consultation (which happens — not everyone qualifies), the consultation fee should be refundable or the platform should clearly state upfront that it's non-refundable.